By Fineline Cube Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that FXS7553 has initiated a Phase 2 clinical trial in China for the treatment of chronic obstructive pulmonary disease (COPD). The compound is a small‑molecule oral DPP‑1 inhibitor independently developed by Fosun Pharma, and no drug with the same molecular mechanism has been approved for marketing in China to date.
Regulatory & Clinical Milestone
| Item | Detail |
|---|---|
| Sponsor | Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) |
| Product | FXS7553 (small‑molecule oral DPP‑1 inhibitor) |
| Stage | Phase 2 clinical trial initiated |
| Indication | Chronic obstructive pulmonary disease (COPD) |
| Market Status | No drug with the same mechanism approved in China |
| Announcement Date | 17 Aug 2026 |
| Next Steps | Phase 2 efficacy and safety evaluation in COPD patients |
Drug Profile & Mechanism of Action
- Molecule: FXS7553, a small‑molecule oral DPP‑1 (dipeptidyl peptidase‑1) inhibitor independently developed by Fosun Pharma
- Mechanism: Inhibits DPP‑1, an enzyme that activates pro‑inflammatory serine proteases in neutrophils, thereby aiming to reduce neutrophil‑driven airway inflammation and damage
- Indication Scope: Intended for the treatment of non‑cystic fibrosis bronchiectasis, COPD, and other indications
- Pipeline Progress: FXS7553 has already entered a Phase 2 trial for non‑cystic fibrosis bronchiectasis, with COPD now becoming the second indication in Phase 2 development
Market Impact & Outlook
- First‑In‑Class Opportunity in China: With no DPP‑1 inhibitor approved for marketing domestically, FXS7553 is positioned in a mechanistically novel space for Chinese respiratory patients.
- Large Disease Burden: COPD affects more than 100 million people in China and remains one of the leading causes of morbidity and mortality, yet treatment options that address underlying neutrophilic inflammation remain limited.
- Multi‑Indication Strategy: Parallel Phase 2 programs in non‑cystic fibrosis bronchiectasis and COPD allow Fosun Pharma to de‑risk development across related neutrophil‑driven respiratory diseases from a single asset.
- Portfolio Expansion: The Phase 2 initiation reinforces Fosun Pharmaceutical’s push to build a differentiated innovative drug pipeline in respiratory medicine alongside its established commercial platforms.
Forward-Looking Statements
This brief contains forward‑looking statements regarding clinical trial conduct, efficacy outcomes, and commercial potential for FXS7553. Actual results may differ due to risks including Phase 2 safety and efficacy data, regulatory decisions, and competitive dynamics in the respiratory disease market.-Fineline Info & Tech